secwatch.observer — SEC 8-K summary
======================================

Issuer:     DYADIC INTERNATIONAL INC (DYAI)
CIK:        0001213809
Form:       8-K
Filed at:   2023-04-12T23:59:59+00:00
Accession:  0001437749-23-010055
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dyadic expands C1 platform licensing deal with Rubic One Health for Africa vaccines and biologics
--------------------------------------------------------------------------------

- Expanded license covers vaccines and therapeutic proteins beyond COVID-19 for human and animal health.
- Rubic to pay licensing fee on commercial sales; Dyadic receives equity in Rubic in 2028.
- Milestones allow conversion to exclusive license for bulk manufacturing in SADC region.
- DYAI-100 (COVID-19 vaccine candidate) is in Phase 1 first-in-human trial, enabling the expansion.
- Agreement aims to develop affordable biologics for underserved African countries.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1213809/000143774923010055/0001437749-23-010055-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1213809/000143774923010055/dyai20230410_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-010055

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer